





# Male

# Female



3 weeks





6 weeks






7 weeks



16 weeks





Time post-glucose injection (min)






**D)**


	Observed	Expected	Chi <sup>2</sup> p-value
WT	57	37.5	p<0.01
Het	82	75	n.s.
Homo	11	37.5	p<0.001

Supplemental Figure 2









**KI67** **Insulin** **DAPI**






4 weeks










Supplemental Figure 8




A)

## 5 week Female Islets




B)


## 5 week Female Islets




C)


## 5 week Male Islets









Supplemental Figure 11



Supplemental Figure 12



## Supp Table 1: Antibody information

Antibody	Host species	Source	Catalog #	Application	Concentration
Insulin	guinea Pig	Thermo Fisher	PA1 26938	IF/IHC	1 to 500
Glucagon	mouse	Sigma	G2654	IF/IHC	1:4000
Ki67	mouse	BD Biosciences	550609	IF	1:1000
DAPI	n/a	SouthernBiotech	0100-20	IF	n/a
MAFA	rabbit	Cell Signaling	79737	IF	1:20,000
Pdx-1	goat	Wright lab	n/a	IF	1:20,000
UCN3	rabbit	Phoenix	H-019-29	IF	1:500
p21	rat	abcam	ab107099	IF	1:200
53BP1	rabbit	Bethyl	A300-272A	IF	1:400
$\gamma$ H2AX	rabbit	abcam	ab81299	IF	1:4000

Tunel assay kit: "In Situ Cell Death Detection Kit Fluorescein", (Roche, Cat# 11684795910)

## Supp Table 2: Primer information

Mouse primers	Forward	Reverse
<i>MafA</i>	CCTGTAGAGGAAGCCGAGGAA	CCTCCCCAGTCGAGTATAGC
<i>Ins1</i>	CACTTCCT ACCCTGCTGG	ACCACAAAGATGCTGTTTGACA
<i>pre-Ins2</i>	GGGGAGCGTGGCTTCTTCTA	GGGGACAGAATTCAGTGGCA
<i>Ins2</i>	CCACCCAGGCTTTTGTCAA	CCCAGCTCCAGTTGTTCCAC
<i>Pdx1</i>	CGGCTGAGCAAGCTAAGGTT	TGGAAGAAGCGCTCTCTTTGA
<i>Ucn3</i>	AGCACCCGGTACAGATACCAA	GGCCTTGTGATGTTGAAGAG
<i>Ankrd1</i>	AAACGGACGGCACTCCACCG	CGCTGTGCTGAGAAGCTTGCTCT
<i>Bcl2a1d</i>	GTATATCCACTCCCTGGCTGAG	TAGTCACAATCCTTCCCCAGTT
<i>Ccl11</i>	TCCACAGCGCTTCTATTCTG	GGAGCCTGGGTGAGCCA
<i>Cd68</i>	ACTTCGGGCCATGTTTCTCT	GCTGGTAGGTTGATTGTCGT
<i>Cxcl12</i>	CAGTAGCGGTAACCCAGTCAGC	TGGCGATGTGGCTCTCG
<i>Icam1</i>	CAATTTCTCATGCCGCACAG	AGCTGGAAGATCGAAAGTCCG
<i>p21</i>	GCCTTAGCCCTACTCT TG	AGCTGGCCTTAGAGGTGACA
<i>Cacng4</i>	TCCGGAAGACGGGACTAC	ATGATGTTGTGGCGTGTCTTG
<i>Chp2</i>	CGCCTAGACCTCCAGCAGATC	GCCTGCGAAATACAGTCTCTGAC
<i>Edn2</i>	CTGGCAAGATGTGGACTGCTGA	GCCTTTCTGTACCTCTGGCT
<i>F2r1</i>	CGGACCCGAGAACCTTGACCCG	GTGAGGATGGACGCAGAGAAT
<i>Grin1</i>	CCTTTTCAGAGCACACTGTGGCT	CCAGGAAAACCATGGCAGAG
<i>Hcn4</i>	CGTGCTCACTAAGGGCAACAAAG	GCACCTCATTGAAGTTGTCCACG
<i>Ret</i>	TTCCAGCATCAACTGCACTG	GTCAGTGGCTACCACCGTGT
<i>Shisa2</i>	TGGCACAACGACCGCCAGCAG	TGAAGGCAACGAACACTGAGCC
<i>Vil1</i>	TTCTACGGTGGTACTGCTACC	TGGTCCAACAGGACGGCTTGAT
<i>β-Actin</i>	AGGTCATCACTATTGGCAACGA	CACCTTCATGATGGAATTGAATGATGT

Human primers	Forward	Reverse
<i>MAFA</i>	GAGAGCGAGAAGTGCCAACCT	TTCTCCTTGTACAGGTCCCG
<i>MAFB</i>	CATAGAGAACGTGGCAGCAA	ATGCCCGGAACCTTTTCTTT
<i>INS</i>	AGAGGCCATCAAGCAGATCACTGT	ACAGGTGTTGGTTCACAAAGGCTG
<i>ANKRD1</i>	AGACTCCTTCAGCCAACATGATG	CTCTCCATCTCTGAAATCCTCAGG
<i>BCL2A1</i>	GGATAAGGCAAAACGGAGGCTG	CAGTATTGCTTCAGGAGAGATAGC
<i>CCL11</i>	GCTACAGGAGAATCACCAGTGG	GGAATCCTGCACCCACTTCTTC
<i>CD68</i>	CGAGCATCATTCTTACCAGCT	ATGAGAGGCAGCAAGATGGACC
<i>CXCL12</i>	CTCAACACTCCAACCTGTGCC	CTCCAGTACTCCTGAATCCAC
<i>ICAM1</i>	AGCGGCTGACGTGTGCAGTAAT	TCTGAGACCTCTGGCTTCGTCA
<i>P21</i>	CCT GTC ACT GTC TTG TAC CCT	GCG TTT GGA GTG GTA GAA ATC T
<i>BCL2</i>	ATCGCCCTGTGGATGACTGAGT	GCCAGGAGAAATCAAACAGAGGC
<i>CXCL2</i>	GGCAGAAAGCTTGTCTCAACCC	CTCCTTCAGGAACAGCCACCAA
<i>ICAM3</i>	AGATCGTCTGCAACGTGACCCT	TCGCTGAGGTTACAATGGGTC
<i>IGFBP2</i>	CGAGGGCACTTGTGAGAAGCG	TGTTTCATGGTGTGCTCCACGTG
<i>IGFBP4</i>	GAGCTGGGTGACACTGCTTG	CCCACGAGGACCTCTACATCA
<i>IGF1R</i>	CTCCTGTTTCTCTCCGCCG	ATAGTCGTTGCGGATGTCGAT
<i>GAPDH</i>	CTCACCGGATGCACCAATGTT	CGCGTTGCTCACAATGTTTCAT

**Supplemental Figure 1: Glucose tolerance phenotypes were stably maintained in male and female *MafA*<sup>S64F/+</sup> mice.** GTT was performed in 3-, 6-, 7-, and 16-week-old mice. Glucose (2mg/kg) was injected following a 6 hour fast and blood glucose was measured at the indicated time points. \*p<0.05; \*\*p<0.01; \*\*\*p<0.001

**Supplemental Figure 2: Homozygous male *MafA*<sup>S64F/S64F</sup> mice were hyperglycemic, with glucose tolerance and blood glucose levels worsening with age.** A) *MafA*<sup>S64F/S64F</sup> mice showed progressively worsening glucose tolerance and fasting blood glucose levels between 5 to 10 weeks of age. B) Fasting blood glucose levels in homozygous male mutant mice increased significantly over time. C) Female S64F *MafA* homozygous mice were only mildly glucose intolerant at 10 weeks of age although their temporal responses to glucose was variable between animals. D) Chi-square analysis revealed that *MafA*<sup>S64F/S64F</sup> male and female animals were observed with significantly less frequency at weaning than WT animals. In contrast, *MafA*<sup>S64F/+</sup> numbers were as expected. \*p<0.05; \*\*p<0.01; \*\*\*p<0.001.

**Supplemental Figure 2: Female *MafA*<sup>S64F/+</sup> islets secreted more insulin in response to low or high glucose.** A) Islet perfusion demonstrated islets from *MafA*<sup>S64F/+</sup> female mice secreted higher levels of insulin at low (G 5.6) and high (G 16.7) glucose and in response to KCl. B) Serum insulin levels (ng/mL) were increased in 6-hour fasted female Het animals while male Het levels were unchanged.

**Supplemental Figure 4: Glucagon secretion was compromised in male and female *MafA*<sup>S64F/+</sup> mice.** A) Glucagon secretion was decreased in S64F *MafA* Het islets, which were incubated in 4.6 mM (LG) and 16.7 mM (HG) glucose for 1 hour prior to collection. Secretion was normalized to glucagon content (B), which was unchanged. Content was normalized to DNA. C) Islet  $\alpha$  cell area was reduced in male S64F *MafA* Het mice, though measurements were highly variable between samples. Islet  $\alpha$  cell area was calculated by dividing the total glucagon<sup>+</sup> area by the total pancreas area (eosin staining) multiplied by 100 to obtain percent (%). \*p<0.05.

**Supplemental Figure 5: Islet  $\beta$  cell proliferation at 4 weeks of age was reduced in both male and female *MafA*<sup>S64F/+</sup> mice.** A) Representative islets stained for insulin, Ki67 (proliferation marker), and DAPI (nuclei). Islet  $\beta$  cell proliferation was calculated by dividing the number of Ki67<sup>+</sup> cells by total insulin<sup>+</sup>  $\beta$  cells. Greater than 1000  $\beta$  cells were counted per sample. \*p<0.05.

**Supplemental Figure 6: Insulin tolerance and glycogen content are unaltered in *MafA*<sup>S64F/+</sup> animals.** A) Insulin tolerance was unchanged at 4 and 5 weeks in Het animals once corrected for initial fasted blood glucose levels (Percent of 0 min). Insulin (0.5U/kg body weight) was injected following a 6 hour fast. B) Glycogen content in muscle (soleus) and liver was also unaffected in 7 week-old S64F *MafA* Het mice. Glycogen content was normalized to wet tissue weight. C) There was no change in average body weight between 3-6 weeks except a small decrease (-1.07 fold) in female S64F *MafA* Het mice at 5 weeks of age. N=5/group, \*p<0.05.

**Supplemental Figure 7: Ovariectomy (OVX) did not alter glucose tolerance in female *MafA*<sup>S64F/+</sup> mice, nor are testosterone levels changed.** A) Compared to 4 week-old control mice (i.e. non OVX: WT, grey line; Het, teal line), the GTT at 1-week post ovariectomy showed glucose intolerance in WT female mice (WT OVX, purple line) and no change in S64F *MafA* Het. \*p<0.05; \*\*p<0.01. B) Serum testosterone levels were unchanged in male or female S64F *MafA* Het. Male and female testosterone levels are similar at 4 and 5 weeks of age.

**Supplemental Figure 8: Male *MafA*<sup>S64F/+</sup> islets had a reduced response to KCl stimulation, while female Het islets had an increased KCl response and baseline Ca<sup>2+</sup>.** A) Representative Ca<sup>2+</sup> traces quantitated in Figure 4C in response to both high glucose (9 mM) and KCl (30 mM). B) Female S64F *MafA* Het islets have increased baseline Ca<sup>2+</sup> at 5mM compared with WT islets (right) while male Het islets do not (left).



**Supplemental Figure 9: qPCR confirmation of changes in islet gene expression identified by RNA-seq.** A) Senescence markers were primarily unchanged in female *MafA*<sup>S64F/+</sup> islets. B) Gene altered specifically in female *MafA*<sup>S64F/+</sup> islets identified by RNA-seq were unchanged in male *MafA*<sup>S64F/+</sup> islets (C). \*p<0.05; \*\*\*p<0.001.

**Supplemental Figure 10: DNA damage and cell cycle inhibition markers were not detected in 5-week-old female *MafA*<sup>S64F/+</sup> islets.** Immunostaining for  $\gamma$ H2AX and 53BP1 (DNA double strand break; A-B), p21 (cell cycle inhibitor; C), and endogenous SA- $\beta$ -gal (senescence marker; D) were not detected in female Het islets.

**Supplemental Figure 11: Significant levels of apoptosis was not found in *MafA*<sup>S64F/+</sup> islet cells.** TUNEL<sup>+</sup> nuclei were barely detected in S64F MafA Het islets at 6 weeks of age but easily visible in DNase treated controls (top panels).

**Supplemental Figure 12: Many X chromosome linked genes were altered in male *MafA*<sup>S64F/+</sup> islets.** Heat map developed from the 5-week-old RNA-Seq data. FDR<0.05.

**Supplemental Figure 13: Production of some  $\beta$  cell identity gene products are downregulated in *MafA*<sup>S64F/+</sup> islets.** A) Heat map showing  $\beta$  identity genes decreased in both male and female Het islets. FDR<0.05. B) Immunostaining illustrating decreased Pdx1 and UCN3 protein levels in 7-week-old S64F MafA Het islets.